The stock has been in free fall since safety issues derailed a gene therapy analysts had expected to achieve blockbuster ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

BofA raised the firm’s price target on Sarepta (SRPT) to $17 from $10 and keeps an Underperform rating on the shares. The firm surveyed 15 ...

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Learn more about whether ADMA Biologics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

A well-connected drug company and Laura Loomer wanted Kennedy ally Vinay Prasad gone. Trump chief of staff Susie Wiles got ...

Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the ...

The biotech, which cut jobs following the rejection in May of its Barth syndrome therapy, claimed it has addressed the agency ...

Kriya is advancing a host of gene therapies for a wide variety of chronic diseases, including geographic atrophy, trigeminal ...